DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/IGF-1 DES
Growth hormone

IGF-1 DES

Also known as: DES(1-3) IGF-1

Truncated IGF-1 variant missing the first three N-terminal residues; reduced IGFBP binding. Research chemical.

C
Grade C
Animal studies only
Human studies3
PubMed citations6
Routesubcutaneous, intramuscular
Regulatory (US)Research only
Last verified2 days ago

Mechanism of action

Native IGF-1 sequence with the first three residues removed, reducing binding to IGFBP-3 and increasing free IGF-1 activity locally.

Evidence summary

3
Human studies
6
PubMed citations
0
Clinical trials
C
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneousintramuscular

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Not FDA approved. Research chemical.

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

No indexed ClinicalTrials.gov studies for IGF-1 DES. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.